{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:18:30Z","timestamp":1770902310112,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014825","name":"BIRAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJID Regions"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijregi.2025.100786","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:47:49Z","timestamp":1760078869000},"page":"100786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and safety of Biological E\u2019s CORBEVAX\u2122 vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD\u2122 or COVAXIN: A prospective double-blind randomized phase III clinical study"],"prefix":"10.1016","volume":"17","author":[{"given":"Subhash","family":"Thuluva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Paradkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SubbaReddy","family":"Gunneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Yerroju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rammohan Reddy","family":"Mogulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Thammireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddalingaiah","family":"Ningaiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Binayke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymaan","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen Chander","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitta Sitaram","family":"Anjaneylu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijregi.2025.100786_bib0001","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARSCoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0002","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0003","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/14760584.2022.2092472","article-title":"Expert review on global realworld vaccine effectiveness against SARSCoV2","volume":"21","author":"Chuenkitmongkol","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijregi.2025.100786_bib0004","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous COVID19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104217","article-title":"Evaluation of safety and immunogenicity of receptor-binding domainbased COVID19 vaccine (CORBEVAX) to select the optimum formulation in openlabel, multicentre phase 1\/2 and phase 2 trials","volume":"83","author":"Thuluva","year":"2022","journal-title":"EBiomedicine"},{"key":"10.1016\/j.ijregi.2025.100786_bib0006","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1016\/j.vaccine.2022.10.045","article-title":"Safety, tolerability and immunogenicity of Biological E's CORBEVAX\u2122 in children and adolescents: a prospective, randomised, double-blind, placebo controlled, phase 2\/3 study","volume":"40","author":"Thuluva","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ijregi.2025.100786_bib0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-1759(95)00127-V","article-title":"Cytokinebased human wholeblood assay for detection of antigenreactive T cells","volume":"186","author":"Petrovsky","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.ijregi.2025.100786_bib0008","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARSCoV2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0009","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARSCoV2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0010","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","article-title":"Effectiveness of a third dose of BNT162b2 mRNA COVID19 vaccine for preventing severe outcomes in Israel","volume":"398","author":"Barda","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijregi.2025.100786_bib0011","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against COVID19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0012","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJMc2200415","article-title":"Effectiveness of homologous or heterologous COVID19 boosters in veterans","volume":"386","author":"Mayr","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijregi.2025.100786_bib0013","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous primeboost COVID19 vaccination (ComCOV): singleblind randomised noninferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijregi.2025.100786_bib0014","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/vaccines12111255","article-title":"Safety and immunogenicity of intranasal Razi Cov Pars as a COVID19 booster in adults: promising results from a groundbreaking clinical trial","volume":"12","author":"Fallah Mehrabadi","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijregi.2025.100786_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1473-3099(22)00427-3","article-title":"Heterologous booster response after inactivated virus BBIBPCorV vaccination in older people","volume":"22","author":"Oviedo Rouco","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijregi.2025.100786_bib0016","article-title":"Safety and efficacy of SOBERANA02 twodose and heterologous SOBERANAPlus threedose COVID19 schedules: phase 3 clinical trial","volume":"18","author":"ToledoRoman\u00ed","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.ijregi.2025.100786_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","article-title":"Proteinsubunit booster after inactivated vaccines enhances neutralising titres against SARSCoV2 variants","volume":"32","author":"Ai","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ijregi.2025.100786_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-069989","article-title":"Effectiveness of heterologous and homologous Covid-19 vaccine regimens: living systematic review with network meta-analysis","volume":"377","author":"Au","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.ijregi.2025.100786_bib0019","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijregi.2025.100786_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102424","article-title":"Humoral antibody kinetics with ChAdOx1-nCOV (Covishield\u2122) and BBV-152 (Covaxin\u2122) vaccine among Indian Healthcare workers: a 6month antibody kinetics after COVISHIELD or COVAXIN vaccination in Indian healthcare workers","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ijregi.2025.100786_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2203632","article-title":"Immunogenicity and safety of Biological E\u2019s CORBEVAX\u2122 vaccine compared with COVISHIELD\u2122 (ChAdOx1 nCoV19) vaccine in a phase-3 single blind, multicentre, randomised clinical trial","volume":"19","author":"Thuluva","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijregi.2025.100786_bib22","volume":"3","author":"Thuluva","year":"2025","journal-title":"Beyond immunogenicity in XBB. 1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply. The Lancet Regional Health-Southeast Asia"},{"key":"10.1016\/j.ijregi.2025.100786_bib23","doi-asserted-by":"crossref","unstructured":"Thuluva S, Paradkar V, Gunneri S, Mogulla RR, Yerroju V, Dhar C, Ningaiah S, Panchakshari M, Gillurkar CS, Narang M, Kisan SS. Safety and immunogenicity of booster doses of an XBB. 1.5 RBD subunit COVID-19 vaccine among individuals aged 5\u201380 years in India: a phase 3, single-blind, randomised controlled trial. The Lancet Regional Health-Southeast Asia. 2025 Sep 1;40.","DOI":"10.1016\/j.lansea.2025.100642"}],"updated-by":[{"DOI":"10.1016\/j.ijregi.2025.100831","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["IJID Regions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772707625002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:24:00Z","timestamp":1770899040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772707625002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"alternative-id":["S2772707625002206"],"URL":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100786","relation":{},"ISSN":["2772-7076"],"issn-type":[{"value":"2772-7076","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of Biological E\u2019s CORBEVAX\u2122 vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD\u2122 or COVAXIN: A prospective double-blind randomized phase III clinical study","name":"articletitle","label":"Article Title"},{"value":"IJID Regions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijregi.2025.100786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"100786"}}